Search Result

Results for "

antitumor and antiangiogenic activities

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (2) Amyloid-β (1) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (10) Autophagy (5) Bacterial (2) c-Kit (7) Endogenous Metabolite (1) ERK (1) Ferroptosis (1) FGFR (6) HDAC (2) HIF/HIF Prolyl-Hydroxylase (1) HIV (2) HSP (2) Integrin (3) Isotope-Labeled Compounds (1) Molecular Glues (1) mTOR (1) Parasite (2) PDGFR (7) Phosphatase (2) PI3K (1) PPAR (1) PTEN (2) Raf (5) Reactive Oxygen Species (1) RET (4) Tie (4) VEGFR (9)
By Research Areas:	Cancer (28) Cardiovascular Disease (5) Infection (5) Inflammation/Immunology (6) Metabolic Disease (3)

By Targets:

ADC Cytotoxin (2)

Amyloid-β (1)

Angiotensin-converting Enzyme (ACE) (1)

Apoptosis (10)

Autophagy (5)

Bacterial (2)

c-Kit (7)

Endogenous Metabolite (1)

ERK (1)

Ferroptosis (1)

FGFR (6)

HDAC (2)

HIF/HIF Prolyl-Hydroxylase (1)

HIV (2)

HSP (2)

Integrin (3)

Isotope-Labeled Compounds (1)

Molecular Glues (1)

mTOR (1)

Parasite (2)

PDGFR (7)

Phosphatase (2)

PI3K (1)

PPAR (1)

PTEN (2)

Raf (5)

Reactive Oxygen Species (1)

RET (4)

Tie (4)

VEGFR (9)

By Research Areas:

Cancer (28)

Cardiovascular Disease (5)

Infection (5)

Inflammation/Immunology (6)

Metabolic Disease (3)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Fat Mass and Obesity-associated Protein (FTO)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19754A

CRA-026440 hydrochloride	HDAC Apoptosis	Cancer
CRA-026440 hydrochloride is a potent, broad-spectrum HDAC (HDAC) inhibitor. The K_i values against recombinant HDAC isoenzymes HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, and HDAC10 are 4 nM, 14 nM, 11 nM, 15 nM, 7 nM, and 20 nM respectively. CRA-026440 hydrochloride shows antitumor and antiangiogenic activities . CRA-026440 (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-133571

Aminohexylgeldanamycin AHGDM	HSP ADC Cytotoxin	Cancer
Aminohexylgeldanamycin (AHGDM), a Geldanamycin derivative, is a potent HSP90 inhibitor. Aminohexylgeldanamycin shows antiangiogenic and antitumor activities .

HY-117737A

RRD-251	Raf Apoptosis	Cancer
RRD-251 is an inhibitor of retinoblastoma tumor suppressor protein (Rb)-Raf-1 interaction, with potent anti-proliferative, anti-angiogenic and anti-tumor activities .

HY-N0205

Pulchinenoside C 1 Publications Verification Anemoside B4	Others	Cancer
Pulchinenoside C (Anemoside B4) is Pulsatilla koreana Nakai that have many numerous biological effects in vitro, including enhancing hypoglycemic, anti-tumor, neuroprotective and anti-angiogenic activity.

HY-133571A

Aminohexylgeldanamycin hydrochloride AHGDM hydrochloride	HSP ADC Cytotoxin	Cancer
Aminohexylgeldanamycin (AHGDM) hydrochloride, a Geldanamycin derivative, is a potent HSP90 inhibitor. Aminohexylgeldanamycin hydrochloride shows antiangiogenic and antitumor activities .

HY-N2732

6-Prenylapigenin 6-Prenyl-4',5,7-trihydroxyflavone; 6-C-Prenylapigenin	Others	Cancer
6-Prenylapigenin is a biologically active flavonoid with anti-tumor activity and antiangiogenic properties. 6-Prenylapigenin exerts cytotoxicity against cancer cells, such as leukemia and solid cancer cells .

HY-115436

LYG-202	Apoptosis	Cancer
LYG-202, a flavonoid, has potent anti-angiogenic and antitumor activity. LYG-202 inhibits VEGF-stimulated HUVEC migration and tube formation. LYG-202 induces cancer cell apoptosis .

HY-N8342

Rhamnazin	VEGFR	Inflammation/Immunology Cancer
Rhamnazin is an orally active inhibitor of VEGFR2 signaling with an IC₅₀ of 4.68 μM against VEGFR2 kinase. Rhamnazin shows potent antiangiogenic activity and antitumor efficacy . Rhamnazin shows antioxidant and anti-inflammatory properties .

HY-100450

BML-111	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease Inflammation/Immunology Cancer
BML-111, a lipoxin A₄ analog, is a lipoxin A₄ receptor agonist. BML-111 represses the activity of angiotensin converting enzyme (ACE) and increases the activity of angiotensinconverting enzyme 2 (ACE2). BML-111 has antiangiogenic, antitumor and anti-inflammatory properties .

HY-156019

FGFR1 inhibitor-10	FGFR	Cancer
FGFR1 inhibitor-10 (Compound 4i) is an FGFR1 inhibitor (IC₅₀: 28 nM). FGFR1 inhibitor-10 inhibits the phosphorylation of FGFR1. FGFR1 inhibitor-10 has anti-angiogenic, anti-invasion activity, and anti-tumor effect .

HY-10330

Toceranib SU11654; PHA 291639E	PDGFR VEGFR c-Kit	Cancer
Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with K_is of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors .

HY-10330A

Toceranib phosphate SU11654 phosphate; PHA 291639E phosphate	PDGFR VEGFR c-Kit	Cancer
Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with K_is of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors .

HY-N2329

Piperlongumine 5+ Cited Publications Piplartine	ERK Reactive Oxygen Species Autophagy Apoptosis Bacterial Ferroptosis	Infection Cardiovascular Disease Cancer
Piperlongumine is a alkaloid , possesses ant-inflammatory, antibacterial, antiangiogenic, antioxidant, antitumor, and antidiabetic activities . Piperlongumine induces ROS, and induces apoptosis in cancer cell lines . Piperlongumine shows anti-cardiac fibrosis activity, suppresses myofibroblast transformation via suppression of the ERK1/2 signaling pathway. Piperlongumin could be used in the study of migrasome .

HY-W592871

10-Hydroxy-2-decenoic acid 10-HDA	mTOR	Cardiovascular Disease Inflammation/Immunology Cancer
10-Hydroxy-2-decenoic acid (10-HDA) is the major lipid component of royal jelly produced by honeybees. 10-Hydroxy-2-decenoic acid has several health-beneficial effects in mammals, such as antitumor activity, anti-inflammatory activity, and antiangiogenic activity. 10-Hydroxy-2-decenoic acid also extends the lifespan of C. elegans .

HY-W008859

Tetrac 1 Publications Verification Tetraiodothyroacetic acid; 3,3',5,5'-Tetraiodothyroacetic acid	Integrin Endogenous Metabolite	Cancer
Tetrac (Tetraiodothyroacetic acid), a derivative of L-thyroxine (T4), is a thyrointegrin receptor antagonist. Tetrac blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on integrin αvβ3. Tetra has anti-angiogenic and anti-tumor activities .

HY-19827

Aeroplysinin 1 (+)-Aeroplysinin-1	Bacterial HIV Apoptosis	Infection Cancer
Aeroplysinin 1 ((+)-Aeroplysinin-1), a secondary metabolite isolated from marine sponges, shows potent antibiotic effects on Gram-positive bacteria and exerts antiviral activity against HIV-1 (IC₅₀=14.6 μM). Aeroplysinin 1 has anti-inflammatory, anti-angiogenic and anti-tumor activities. Aeroplysinin 1 induces apoptosis in endothelial cells .

HY-10331

Regorafenib Maximum Cited Publications 47 Publications Verification BAY 73-4506	VEGFR Autophagy PDGFR Raf RET c-Kit FGFR Tie	Cancer
Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity .

HY-10331A

Regorafenib monohydrate Maximum Cited Publications 47 Publications Verification BAY 73-4506 monohydrate	VEGFR Autophagy PDGFR Raf RET FGFR c-Kit Tie	Cancer
Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity .

HY-13737

R1530 1 Publications Verification	VEGFR FGFR Apoptosis	Cancer
R1530 is a highly potent, orally active, dual-acting mitosis/angiogenesis inhibitor, with anti-tumor and anti-angiogenic activities. R1530 is a multikinase inhibitor which binds to 31 kinases with K_d values of <500 nM. R1530 inhibits VGFR2 and FGFR1 with IC₅₀ of 10 nM and 28 nM, respectively. R1530 triggers apoptosis (mitotic catastrophe) or senescence .

HY-10220

SF1126	PI3K Apoptosis	Cancer
SF1126 is a relevant pan and dual first-in-class PI3K/BRD4 inhibitor, has antitumor and anti-angiogenic activity. SF1126 is an RGDS-conjugated LY294002 proagent, which is designed to exhibit increased solubility and bind to specific integrins within the tumor compartment. SF1126 induces cell apoptosis .

HY-10331B

Regorafenib mesylate BAY 73-4506 mesylate	VEGFR PDGFR RET Raf c-Kit FGFR Autophagy Tie	Cancer
Regorafenib (BAY 73-4506) mesylate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib mesylate shows very robust antitumor and antiangiogenic activity .

HY-10330S

Toceranib-d8	Isotope-Labeled Compounds PDGFR VEGFR c-Kit	Cancer
Toceranib-d₈ is the deuterium labeled Toceranib. Toceranib (SU11654) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib (SU11654) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors[1][2].

HY-P99333

Volociximab M200; Eos 200-4	Integrin	Cardiovascular Disease Cancer
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC₅₀=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) .

HY-N6924

Zingibroside R1	HIV	Infection Metabolic Disease
Zingibroside R1 is dammaranae-type triterpenoid saponin, isolated from rhizomes, taproots, and lateral roots of Panax japonicas C. A. Meyer, shows excellent anti-tumor effects as well as anti-angiogenic activity . Zingibroside R1 possesses some anti-HIV-1 activity. Zingibroside R1 has inhibitory effects on the 2-deoxy-D-glucose (2-DG) uptake by EAT cells (IC₅₀=91.3 μM) .

HY-10331R

Regorafenib (Standard)	VEGFR Autophagy PDGFR Raf RET c-Kit FGFR Tie	Cancer
Regorafenib (Standard) is the analytical standard of Regorafenib. This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity .

HY-N0234

Bavachinin 2 Publications Verification 7-O-Methylbavachin; Bavachinin A	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology
Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-14571

E7820 4 Publications Verification ER68203-00	Molecular Glues Integrin	Cancer
E7820 (ER68203-00), an orally active aromatic sulfonamide derivative, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. E7820 inhibits rat aorta angiogenesis with an IC₅₀ of 0.11 μg/ml. E7820 modulates α-1, α-2, α-3, and α-5 integrin mRNA expression. Antiangiogenic and antitumor activity .

HY-19754

CRA-026440	HDAC Apoptosis	Cardiovascular Disease Cancer
CRA-026440 is a potent, broad-spectrum HDAC inhibitor. The K_i values against recombinant HDAC isoenzymes HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, and HDAC10 are 4, 14, 11, 15, 7, and 20 nM respectively. CRA-026440 shows antitumor and antiangiogenic activities . CRA-026440 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-136065

bpV(phen)	PTEN Phosphatase Parasite Apoptosis	Infection Metabolic Disease Inflammation/Immunology Cancer
bpV(phen), a insulin-mimetic agent, is a potent protein tyrosine phosphatase (PTP) and PTEN inhibitor with IC₅₀s of 38 nM, 343 nM and 920 nM for PTEN, PTP-β and PTP-1B, respectively. bpV(phen) inhibits proliferation of the protozoan parasite Leishmania in vitro. bpV(phen) strongly induces the secretion of a large number of chemokines and pro-inflammatory cytokines, and it activates a Th1-type pathway (IL-12, IFNγ). bpV(phen) can also induce cell apoptosis, and has anti-angiogenic and anti-tumor activity .

HY-122818

bpV(phen) trihydrate 2 Publications Verification	PTEN Phosphatase Parasite Apoptosis	Infection Metabolic Disease Inflammation/Immunology Cancer
bpV(phen) trihydrate, a insulin-mimetic agent, is a potent protein tyrosine phosphatase (PTP) and PTEN inhibitor with IC₅₀s of 38 nM, 343 nM and 920 nM for PTEN, PTP-β and PTP-1B, respectively. bpV(phen) trihydrate inhibits proliferation of the protozoan parasite Leishmania in vitro. bpV(phen) trihydrate strongly induces the secretion of a large number of chemokines and pro-inflammatory cytokines, and it activates a Th1-type pathway (IL-12, IFNγ). bpV(phen) trihydrate can also induce cell apoptosis, and has anti-angiogenic and anti-tumor activity .

Volociximab M200; Eos 200-4	Integrin	Cardiovascular Disease Cancer
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC₅₀=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) .

Cat. No.	Product Name	Category	Target	Chemical Structure